Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a transcription factor that plays a central role in cellular defense against oxidative and electrophilic stress. It regulates the expression of genes containing antioxidant response elements (AREs), leading to increased production of cytoprotective proteins. Nrf2 influences metabolism, inflammation, autophagy, proteostasis, mitochondrial function, and immune responses. Dysregulation of Nrf2 is implicated in diseases such as cancer, atherosclerosis, and liver injury. Therapeutic strategies are being explored to modulate Nrf2 activity.
Under non-stressed conditions, Keap1 binds to the Neh2 domain on Nrf2, promoting ubiquitination and degradation. Upon oxidative/electrophilic stress, Keap1 is modified/inhibited, releasing Nrf2. Stabilized Nrf2 accumulates/translocates into the nucleus, forms heterodimers with small Maf proteins, binds ARE sequences on DNA promoters, and initiates transcription of cytoprotective/antioxidant/detoxification genes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear factor (erythroid-derived 2)-like 2 (Nrf2).